Bayer cuts four programs amid a 'slow start' to the year
15 May 2023
Phase 2Phase 1Financial Statement
Bayer announced a handful of pipeline cuts in its quarterly earnings report last week, as CEO Werner Baumann revealed the quarter “came in soft” compared to last year’s performance.
The culls include two Phase II programs, a BDKRB1 receptor antagonist for neuropathic pain, and runcaciguat, in development for chronic kidney disease. The BDKRB1 receptor plays a role in pain perception, and Bayer’s candidate, BAY 2395840, came out of a research alliance with Evotec. The company also said it’s discontinuing a Phase I program studying BAY 2395840 in endometriosis.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 168,600+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.